AEterna Zentaris (AEZS)
(Delayed Data from NSDQ)
$7.79 USD
-0.37 (-4.53%)
Updated Jun 5, 2024 12:27 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
AEterna Zentaris Inc. [AEZS]
Reports for Purchase
Showing records 1 - 20 ( 168 total )
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Revenue Miss; Pipeline Path Unclear; 3Q23 Financials; Lowering PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Progress; 2Q23 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Steady Pipeline Progress; Runway Guidance Reconfirmed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Macrilen Temporary Sales Discontinuation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Reprioritization; Runway Extended; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Awaiting Macimorelin Partnering Update; 3Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Macimorelin North American Rights Returned; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Macimorelin Launched in Europe; 2Q22 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Reverse Split Share Consolidation Takes Effect; Adjusting PT to $28
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
AIM Biologicals Program Proof-of-Concept Data Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
European Patent Portfolio Expanded; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
DETECT Trial Enrollment Delays; 2021 Financials; Lowering PT to $1.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Research Collaboration Expanded to Advance Oral Vaccines; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Updates and 2022 Outlook Announced; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: AEterna Zentaris Inc.
Industry: Medical - Biomedical and Genetics
A Triple Threat, at Least; Initiating at Buy and $2 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R